Figure legends:
Figure 1. CD15+LOX-1+ PMN-MDSC frequency in the circulation of healthy donors and NSCLC patients.
The frequency of circulating CD15+LOX-1+ PMN-MDSCs in healthy donors (n=50) and NSCLC patients (n=50) were measured by FCM. (B)ARG1 expression was detected in PB of healthy donors (n=50) and NSCLC patients (n=50). (C) The correlation analysis between CD15+LOX-1+ PMN-MDSC frequency andARG1 expression in NSCLC patients (n=50). ***P <0.001.
Figure 2. The potential application of CD15+LOX-1+ PMN-MDSCs in NSCLC diagnosis.
(A) Levels of CEA, CYFRA21-1, and CA125 in serum of NSCLC patients were measured (n=50). (B) The correlation of CD15+LOX-1+ PMN-MDSC frequency with levels of tumor markers. (C) ROC curves. ***P <0.001.
Figure 3. Circulating CD15+LOX-1+PMN-MDSCs are associated with NSCLC prognosis and recurrence after surgery.
(A) CD15+LOX-1+ PMN-MDSC frequency in PB of NSCLC patients before (n=50) or after surgical resection (n=50). (B) CD15+LOX-1+ PMN-MDSC frequency in PB of NSCLC patients with (n=50) or without (n=50) recurrence post-surgery. (C) CD15+LOX-1+ PMN-MDSC frequency was compared in traced NSCLC patients with (n=8) or without (n=3) recurrence post-surgery. **P <0.01, ***P <0.001.